PARP inhibition in platinum-based chemotherapy: Chemopotentiation and neuroprotection
Rachel M McQuade, Vanesa Stojanovska, Joel C Bornstein, Kulmira Nurgali
PHARMACOLOGICAL RESEARCH | ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD | Published : 2018
Cisplatin, carboplatin and oxaliplatin represent the backbone of platinum therapy for several malignancies including head and neck, lung, colorectal, ovarian, breast, and genitourinary cancer. However, the efficacy of platinum-based drugs is often compromised by a plethora of severe toxicities including sensory and enteric neuropathy. Acute and chronic neurotoxicity following platinum chemotherapy is a major constraint, contributing to dose-reductions, treatment delays, and cessation of treatment. Identifying drugs that effectively prevent these toxic complications is imperative to improve the efficacy of anti-cancer treatment and patient quality of life. Oxidative stress and mitochondrial d..View full abstract
This study was supported by Victoria University (Australia) Research Development Grant. RMM is supported by the College of Health and Biomedicine, Victoria University, Australia.